Core Points - China National Pharmaceutical Group Corporation (referred to as "China Pharmaceutical") disclosed a lawsuit update on November 22, involving a performance compensation contract dispute amounting to 139.4041 million yuan (approximately 1.39 billion yuan) [1] - The lawsuit originated from a performance compensation contract dispute that occurred in October 2024, with China Pharmaceutical as the plaintiff against Tibet Tiansheng Taifeng Pharmaceutical Co., Ltd. and Xu Panfeng [1] - The first-instance court has made a civil judgment, but both China Pharmaceutical and Tibet Tiansheng have appealed the decision, and the case is currently in the second-instance stage, awaiting trial [1] Summary by Sections Lawsuit Details - The lawsuit involves a total amount of 139.4041 million yuan, primarily concerning disputes over the performance compensation contract [1] - As of the announcement date, the second-instance trial has not yet commenced, and the final outcome remains uncertain [1] Company Actions - China Pharmaceutical has previously disclosed relevant information regarding the lawsuit through temporary announcements and regular reports on October 12, 2024, and October 11, 2025 [1]